Genesee Valley Trust Co. Sells 1,481 Shares of Eli Lilly and Co (LLY)
Genesee Valley Trust Co. cut its position in Eli Lilly and Co (NYSE:LLY) by 33.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,943 shares of the company’s stock after selling 1,481 shares during the quarter. Genesee Valley Trust Co.’s holdings in Eli Lilly and were worth $249,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in the business. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in Eli Lilly and by 1.9% in the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,953,852 shares of the company’s stock worth $249,482,000 after purchasing an additional 56,324 shares in the last quarter. Aries Wealth Management bought a new position in Eli Lilly and in the fourth quarter worth about $219,000. Crossmark Global Holdings Inc. raised its holdings in Eli Lilly and by 7.9% in the fourth quarter. Crossmark Global Holdings Inc. now owns 111,295 shares of the company’s stock worth $9,400,000 after purchasing an additional 8,112 shares in the last quarter. Palladium Partners LLC raised its holdings in Eli Lilly and by 3.5% in the fourth quarter. Palladium Partners LLC now owns 214,593 shares of the company’s stock worth $18,125,000 after purchasing an additional 7,290 shares in the last quarter. Finally, Calton & Associates Inc. bought a new position in Eli Lilly and in the fourth quarter worth about $237,000. Institutional investors and hedge funds own 76.45% of the company’s stock.
Shares of Eli Lilly and Co (LLY) opened at $76.72 on Thursday. The company has a market capitalization of $85,874.41, a P/E ratio of -383.58, a P/E/G ratio of 1.43 and a beta of 0.23. Eli Lilly and Co has a 52-week low of $75.71 and a 52-week high of $89.09. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03.
The company also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be given a $0.5625 dividend. The ex-dividend date is Wednesday, February 14th. This represents a $2.25 dividend on an annualized basis and a yield of 2.93%. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s dividend payout ratio is currently -1,039.95%.
In related news, SVP Alfonso G. Zulueta sold 2,003 shares of the company’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $83.67, for a total value of $167,591.01. Following the sale, the senior vice president now owns 43,580 shares in the company, valued at $3,646,338.60. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total value of $17,640,000.00. Following the completion of the sale, the insider now owns 123,084,104 shares in the company, valued at approximately $10,856,017,972.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 261,613 shares of company stock worth $22,894,997. 0.20% of the stock is owned by insiders.
A number of brokerages have commented on LLY. Bank of America reduced their target price on shares of Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating for the company in a report on Thursday, February 1st. Credit Suisse Group restated a “hold” rating and set a $80.00 price objective on shares of Eli Lilly and in a report on Friday, February 2nd. BMO Capital Markets upped their price objective on shares of Eli Lilly and from $73.00 to $74.00 and gave the company an “underperform” rating in a report on Thursday, February 1st. Piper Jaffray Companies restated a “buy” rating and set a $105.00 price objective on shares of Eli Lilly and in a report on Friday, October 13th. Finally, Jefferies Group set a $100.00 price objective on shares of Eli Lilly and and gave the company a “buy” rating in a report on Tuesday, January 16th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $92.02.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.